Price$165.10+0.43 (+0.26%)
01:30 PM02:00 PM
News · 26 weeks147-43%
2026-02-152026-08-09
Mix8090d
- Insider54(68%)
- Other10(13%)
- SEC Filings9(11%)
- Analyst5(6%)
- Earnings2(3%)
Latest news
25 items- INSIDERCo-Chief Executive Officer Eltoukhy Helmy gifted 35,000 shares and received a gift of 35,000 shares (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERCo-Chief Executive Officer Talasaz Amirali gifted 75,000 shares and received a gift of 75,000 shares (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Legal Officer Saia John G. gifted 800 shares, decreasing direct ownership by 2% to 38,991 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Commercial Officer Freeman Chris exercised 63,605 shares at a strike of $74.09 and sold $10,786,111 worth of shares (63,605 units at $169.58) (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- PRGuardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units ("RSUs") representing 46,044 shares of its common stock to 149 new non-executive employees with a grant date of August 3, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who w
- INSIDERDirector Hidalgo Medina Manuel sold $279,202 worth of shares (1,700 units at $164.24) and exercised 950 shares at a strike of $32.55, decreasing direct ownership by 14% to 4,556 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Clark Ian T exercised 9,088 shares at a strike of $60.63 and sold $2,253,451 worth of shares (14,180 units at $158.92) (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- SECSEC Form 144 filed by Guardant Health Inc.144 - Guardant Health, Inc. (0001576280) (Subject)
- SECSEC Form S-3ASR filed by Guardant Health Inc.S-3ASR - Guardant Health, Inc. (0001576280) (Filer)
- SECSEC Form 10-Q filed by Guardant Health Inc.10-Q - Guardant Health, Inc. (0001576280) (Filer)
- SECGuardant Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Guardant Health, Inc. (0001576280) (Filer)
- PRGuardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue GuidanceSecond quarter 2026 revenue growth of 44% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights For the three-month period ended June 30, 2026, as compared to the same period of 2025: Reported total revenue of $335.0 million, an increase of 44%, driven by: Oncology revenue of $219.1 million, an increase of 38%, and approximately 104,000 oncology tests, an increase of 63% Biopharma & Data revenue of $60.9
- PRGuardant Health to Participate in Upcoming Investor ConferencesGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Canaccord Genuity 46th Annual Growth Conference in Boston, MA Fireside chat on Wednesday, August 12th at 3:00 p.m. Eastern Time Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY Fireside chat on Tuesday, September 15th at 7:45 a.m. Eastern Time Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellnes
- PRActor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal CancerDempsey is calling on Americans to prioritize getting screened and highlighting the innovative Shield blood test for CRC screening Guardant's Shield blood test is the only FDA-approved blood test included in both ACS and NCCN screening guidelines Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a new video featuring actor and cancer advocate Patrick Dempsey that highlights the more than 55,000 Americans who will lose their lives to colorectal cancer (CRC) this year1, a majority of which will not have been up to date with their colorectal cancer screening.2 This press release features multimedia. View the full release here: https:
- INSIDERDirector Mignone Roberto converted options into 264 shares, increasing direct ownership by 3% to 9,746 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 5% to 5,306 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Tariq Musa converted options into 250 shares and sold $18,942 worth of shares (116 units at $163.29), increasing direct ownership by 1% to 11,182 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- PRGuardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, G
- INSIDERChief Legal Officer Saia John G. converted options into 7,063 shares and covered exercise/tax liability with 3,707 shares, increasing direct ownership by 9% to 39,791 units (SEC Form 4) (withholding obligation)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief People Officer Monroe Terilyn J. converted options into 4,020 shares and covered exercise/tax liability with 2,099 shares, increasing direct ownership by 9% to 22,979 units (SEC Form 4) (tax withholding)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Information Officer Kalia Kumud converted options into 6,046 shares and covered exercise/tax liability with 3,066 shares, increasing direct ownership by 7% to 43,794 units (SEC Form 4) (tax withholding)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Commercial Officer Freeman Chris converted options into 7,414 shares and covered exercise/tax liability with 3,141 shares, increasing direct ownership by 7% to 65,374 units (SEC Form 4) to satisfy withholding obligation4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Technology Officer Chudova Darya converted options into 8,030 shares and covered exercise/tax liability with 4,318 shares, increasing direct ownership by 5% to 78,373 units (SEC Form 4) to satisfy withholding tax4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Financial Officer Bell Michael Brian converted options into 7,278 shares and covered exercise/tax liability with 3,914 shares, increasing direct ownership by 7% to 51,816 units (SEC Form 4) (tax liability)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERCo-Chief Executive Officer Eltoukhy Helmy converted options into 36,529 shares and covered exercise/tax liability with 18,514 shares (SEC Form 4) (withholding tax)4 - Guardant Health, Inc. (0001576280) (Issuer)
GH FAQ
7 questionsWhat does Guardant Health Inc. do?
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic...Where does GH stock trade?
Guardant Health Inc. (GH) is listed on NASDAQ.What sector and industry is GH in?
Guardant Health Inc. operates in the Health Care sector, Medical Specialities industry.When did Guardant Health Inc. go public?
Guardant Health Inc. (GH) completed its IPO in 2018.What are analysts saying about GH?
Guardant Health Inc. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Outperform on 2026-06-26.What companies are similar to GH?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare GH side-by-side with any of them on Quantisnow.How can I track GH on Quantisnow?
Quantisnow aggregates Guardant Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GH to receive live email and push alerts on every new disclosure.